These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 2107064

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.
    Jones RN, Barry AL, Thornsberry C.
    Antimicrob Agents Chemother; 1989 Jun; 33(6):944-50. PubMed ID: 2504106
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.
    Rolston KV, Nguyen HT, Ho DH, LeBlanc B, Bodey GP.
    Antimicrob Agents Chemother; 1992 Apr; 36(4):879-82. PubMed ID: 1503453
    [Abstract] [Full Text] [Related]

  • 10. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
    Spangler SK, Jacobs MR, Pankuch GA, Appelbaum PC.
    J Antimicrob Chemother; 1993 Feb; 31(2):273-80. PubMed ID: 8463172
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial activity of Ro 24-6778, a covalent bonding of desmethylfleroxacin and desacetylcefotaxime.
    Jones RN.
    Diagn Microbiol Infect Dis; 1990 Feb; 13(3):253-9. PubMed ID: 2116952
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS, Mazens-Sullivan MF, Bartlett RC.
    Chemotherapy; 1992 Feb; 38(5):308-18. PubMed ID: 1337507
    [Abstract] [Full Text] [Related]

  • 17. Low-level resistance to the cephalosporin 3'-quinolone ester Ro 23-9424 in Escherichia coli.
    Chapman JS, Bertasso A, Cummings LM, Georgopapadakou NH.
    Antimicrob Agents Chemother; 1995 Feb; 39(2):564-6. PubMed ID: 7726536
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB, Swanson RN.
    Drugs Exp Clin Res; 1988 Feb; 14(6):375-8. PubMed ID: 3145851
    [Abstract] [Full Text] [Related]

  • 20. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
    Aoyama H, Inoue M, Mitsuhashi S.
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():99-114. PubMed ID: 2849604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.